Fondaparinux
| Clinical data | |
|---|---|
| Trade names | Arixtra | 
| AHFS/Drugs.com | Monograph | 
| License data | 
 | 
| Routes of administration | Subcutaneous | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A | 
| Protein binding | 94% | 
| Metabolism | renally excreted unchanged | 
| Elimination half-life | 17-21 hours | 
| Identifiers | |
| CAS Number | 
 | 
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | 
 | 
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C31H43N3Na10O49S8 | 
| Molar mass | 1728.03 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by Viatris. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.